Monopar Therapeutics Files 8-K
Ticker: MNPR · Form: 8-K · Filed: Jun 10, 2024 · CIK: 1645469
| Field | Detail |
|---|---|
| Company | Monopar Therapeutics (MNPR) |
| Form Type | 8-K |
| Filed Date | Jun 10, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, 8-K
TL;DR
Monopar filed an 8-K, standard procedure, no major news yet.
AI Summary
On June 10, 2024, Monopar Therapeutics Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements/exhibits. No specific material events, financial figures, or new developments were detailed in the provided excerpt.
Why It Matters
This filing indicates Monopar Therapeutics is complying with regulatory requirements for reporting material information and financial updates to the public.
Risk Assessment
Risk Level: low — The filing is a routine disclosure and does not contain information that inherently increases or decreases risk.
Key Players & Entities
- Monopar Therapeutics Inc. (company) — Registrant
- June 10, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-39070 (identifier) — Commission File Number
- 32-0463781 (identifier) — I.R.S. Employer Identification No.
- 1000 Skokie Blvd. , Suite 350 , Wilmette , IL 60091 (address) — Address of principal executive offices
- 847-388-0349 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing by Monopar Therapeutics?
The filing is primarily for Regulation FD disclosures and to report financial statements and exhibits, as indicated by the 'ITEM INFORMATION' section.
When was the earliest event reported in this filing?
The earliest event reported is dated June 10, 2024.
In which state is Monopar Therapeutics incorporated?
Monopar Therapeutics Inc. is incorporated in Delaware.
What is the principal executive office address for Monopar Therapeutics?
The principal executive offices are located at 1000 Skokie Blvd., Suite 350, Wilmette, IL 60091.
Does this filing excerpt detail any specific new business developments or financial results?
No, the provided excerpt of the 8-K filing does not detail specific new business developments or financial results; it focuses on the filing's nature and the company's basic information.
Filing Stats: 455 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-06-10 08:00:17
Key Financial Figures
- $0.001 — ge on which registered Common Stock , $0.001 par value MNPR The Nasdaq Stock Mar
Filing Documents
- mnpr20240608c_8k.htm (8-K) — 25KB
- ex_685709.htm (EX-99.1) — 9KB
- mt01.jpg (GRAPHIC) — 6KB
- 0001437749-24-019747.txt ( ) — 182KB
- mnpr-20240610.xsd (EX-101.SCH) — 3KB
- mnpr-20240610_def.xml (EX-101.DEF) — 12KB
- mnpr-20240610_lab.xml (EX-101.LAB) — 16KB
- mnpr-20240610_pre.xml (EX-101.PRE) — 12KB
- mnpr20240608c_8k_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On June 10, 2024, Monopar Therapeutics Inc. (Monopar) issued a press release announcing a poster presentation summarizing data from the preclinical development of its novel first-in-class lead radiopharma program MNPR-101-Zr at the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting in Toronto, Canada. The press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits Exhibit No. Description 99.1 Press Release Dated June 10, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Monopar Therapeutics Inc. Date: June 10, 2024 By: /s/ Kim R. Tsuchimoto Name: Kim R. Tsuchimoto Title: Chief Financial Officer and Director